The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice

Kidney International

Volumn 85, Issue 1, 2014, Pages 134-141

  Liu, Manchang ^a   Reddy, Narsa M ^b   Higbee, Elizabeth M ^a   Potteti, Haranatha R ^b   Noel, Sanjeev ^a   Racusen, Lorraine ^a   Kensler, Thomas W ^c   Sporn, Michael B ^d   Reddy, Sekhar P ^b   Rabb, Hamid ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

acute kidney injury; inflammation; ischemia reperfusion; oxidative stress; reactive oxygen species

Indexed keywords

BARDOXOLONE; CREATININE; GLUTATHIONE PEROXIDASE 2; HEME OXYGENASE 1; IMIDAZOLIDE; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CYTOKINE PRODUCTION; GENE EXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION;

ACUTE KIDNEY INJURY; ANIMALS; ANOXIA; CYTOKINES; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; FEMALE; IMIDAZOLES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; REPERFUSION INJURY; TRANSCRIPTIONAL ACTIVATION;

EID: 84891561133     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.357     Document Type: Article

References (31)

1. Ali T, Khan I, Simpson W et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298. (Pubitemid 46536915)
2. Ojo AO, Wolfe RA, Held PJ et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-974. (Pubitemid 27173019)
3. Mehrotra A, Rose C, Pannu N et al. Incidence and consequences of acute kidney injury in kidney transplant recipients. Am J Kidney Dis 2012; 59: 558-565.
4. Baker GL, Corry RJ, Autor AP. Oxygen free-radical induced damage in kidneys subjected to warm ischemia and reperfusion - protective effect of superoxide-dismutase. Ann Surg 1985; 202: 628-641. (Pubitemid 16245048)
5. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med 2000; 109: 665-678.
6. Leonard MO, Kieran NE, Howell K et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 2006; 20: 2624-2626.
7. Liu M, Grigoryev DN, Crow MT et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009; 76: 277-285.
8. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
9. Walker LM, York JL, Imam SZ et al. Oxidative stress and reactive nitrogen species generation during renal ischemia. Toxicol Sci 2001; 63: 143-148. (Pubitemid 32799034)
10. Sen C, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10: 709-720. (Pubitemid 26172817)
11. Small DM, Coombes JS, Bennett N et al. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 2012; 17: 311-321.
12. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 1-43. (Pubitemid 350161567)
13. Suh N, Wang Y, Honda T et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999; 59: 336-341. (Pubitemid 29048864)
14. Koschmieder S, D'Alo F, Radomska H et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational upregulation of p42 CCAAT enhancer binding protein alpha. Blood 2007; 110: 3695-3705. (Pubitemid 350159639)
15. Liby K, Hock T, Yore MM et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ ARE signaling. Cancer Res 2005; 65: 4789-4798. (Pubitemid 40740817)
16. Aleksunes LM, Goedken MJ, Rockwell CE et al. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 2010; 335: 2-12.
17. Reisman SA, Buckley DB, Tanaka Y et al. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol 2009; 236: 109-114.
18. Zhang F, Wang S, Zhang M et al. Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury. Stroke 2012; 43: 1390-1397.
19. Reddy NM, Suryanaraya V, Yates MS et al. The triterpenoid CDDOimidazolide confers potent protection against hyperoxic acute lung injury in mice. Am J Respir Crit Care Med 2009; 180: 867-874.
20. Sussan TE, Rangasamy T, Blake DJ et al. Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009; 106: 250-255.
21. Thimmulappa RK, Scollick C, Traore K et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDOImidazolide. Biochem Biophys Res Commun 2006; 351: 883-889. (Pubitemid 44715868)
22. Yates MS, Tran QT, Dolan PM et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-Treated mice. Carcinogenesis 2009; 30: 1024-1031.
23. Yates MS, Kwak M-K, Egner PA et al. Potent protection against aflatoxininduced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28- oyl]imidazole. Cancer Res 2006; 66: 2488-2494.
24. Yore MM, Kettenbach AN, Sporn MB et al. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One 2011; 6: e22862.
25. Osburn WO, Yates MS, Dolan PD et al. Genetic or pharmacologic amplification of Nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci 2008; 104: 218-227. (Pubitemid 351859044)
26. Pergola PE, Krauth M, Huff JW et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2011; 33: 469-476.
27. Wu QQ, Wang Y, Senitko M et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2 PPARgamma, and HO-1. Am J Physiol Renal Physiol 2011; 300: F1180-F1192.
28. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 2000; 20: 4-19. (Pubitemid 30048825)
29. Itoh K, Chiba T, Takahashi S et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322. (Pubitemid 27373291)
30. Liby K, Hock T, Yore MM et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ ARE signaling. Cancer Res 2005; 65: 4789-4798. (Pubitemid 40740817)
31. Yates MS, Tauchi M, Katsuoka F et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007; 6: 154-162. (Pubitemid 46206678)